am833 semaglutide 1/ Future of Obesity Treatments? #OW2021 Meet the candidates: 1) +/- 2.4 mg; combo therapy resulted in 15-17% at 20 weeks with no evidence of nadir, suggesting even greater wt loss (likely >20%). by Dr. Rubino AM833 Is a Novel Agonist

It also helps regulate blood sugar and increases insulin secretion, which can boost metabolic health

These dosing conditions have been used in the oral semaglutide phase 3 trials and are part of the approved label

Primary and secondary outcome measures Change in HbA1c (primary endpoint) and BW (confirmatory secondary endpoint) from baseline to week 40

Manganese (as Albion Manganese Bisglycinate Chelate)

This is largely driven by rapid gastric emptying and an exaggerated GLP-1 mediated insulin response, particularly after Roux-en-Y gastric bypass (RYGB)

Read Pienomial's insights on this key clinical development for diabetes.